Questões de Inglês

Stocks headed for early bounce

By CNNMoney staff October 14, 2011: 8:43 AM ET

  NEW YORK (CNNMoney) -- U.S. stocks were headed for a bounce Friday, as investors welcomed strong earnings from Google and geared up for an onslaught of fresh economic data.

  Dow Jones industrial average (INDU), S&P 500 (SPX) and Nasdaq (COMP) futures were up slightly ahead of the opening bell. Stock futures indicate the possible direction of the markets when they open at 9:30 a.m. ET.[..].

  Better news came after the bell though, as Google (GOOG, Fortune 500) reported a stronger-than-expected third-quarter profit. Google shares jumped more than 6% in premarket trading.

(Disponível em: . Acesso em: 14 out. 2011).

Stocks headed for early bounce

By CNNMoney staff October 14, 2011: 8:43 AM ET

  NEW YORK (CNNMoney) -- U.S. stocks were headed for a bounce Friday, as investors welcomed strong earnings from Google and geared up for an onslaught of fresh economic data.

  Dow Jones industrial average (INDU), S&P 500 (SPX) and Nasdaq (COMP) futures were up slightly ahead of the opening bell. Stock futures indicate the possible direction of the markets when they open at 9:30 a.m. ET.[..].

  Better news came after the bell though, as Google (GOOG, Fortune 500) reported a stronger-than-expected third-quarter profit. Google shares jumped more than 6% in premarket trading.

(Disponível em: . Acesso em: 14 out. 2011).

Jobs‘s Unorthodox Treatment

By SHARON BEGLEY

Published: Oct 5, 2011

  Steve Jobs was right to be optimistic when, in 2004, he announced that he had cancer in his pancreas. Although cancer of the pancreas has a terrible prognosis—half of all patients with locally advanced pancreatic cancer die within 10 months of the diagnosis; half of those in whom it has metastasized die within six months—cancer in the pancreas is not necessarily a death sentence.

  The difference is that pancreatic cancers arise from the pancreatic cells themselves; this is the kind that killed actor Patrick Swayze in 2009. But cancers in the pancreas, called neuroendocrine tumors, arise from islands of hormone-producing cells that happen to be in that organ. Jobs learned in 2003 that he had an extremely rare form of this cancer, an islet-cell neuroendocrine tumor. As the name implies, it arises from islet cells, the specialized factories within the pancreas that produce and secrete insulin, which cells need in order to take in glucose from the food we eat. Unlike pancreatic cancer, with neuroendocrine cancer ''if you catch it early, there is a real potential for cure,'' says cancer surgeon Joseph Kim of City of Hope, a comprehensive cancer center in Duarte, California.

  But although neither Apple nor those close to Jobs were willing to discuss the treatments he elected or the course of his disease, interviews with experts on neuroendocrine tumors suggest that some of the choices he made did not extend his life and may have shortened it. [...] Despite the expert consensus on the value of surgery, Jobs did not elect it right away. He reportedly spent nine months on ''alternative therapies,'' including what Fortune called ''a special diet.'' But when a scan showed that the original tumor had grown, he finally had it removed on July 31, 2004, at Stanford University Medical Clinic. In emails to Apple employees immediately after, Jobs said his form of cancer ''can be cured by surgical removal if diagnosed in time (mine was),'' and told his colleagues, ''I will be recuperating during the month of August, and expect to return to work in September.''

(Disponível em: <http://www.thedailybeast.com/articles/2011/10/05/steve-jobs-dies-hisunorthodox-treatment-for-neuroendocrine-cancer.html?obref=obinsite>. Acesso em: 5 out. 2011).

Jobs‘s Unorthodox Treatment

By SHARON BEGLEY

Published: Oct 5, 2011

  Steve Jobs was right to be optimistic when, in 2004, he announced that he had cancer in his pancreas. Although cancer of the pancreas has a terrible prognosis—half of all patients with locally advanced pancreatic cancer die within 10 months of the diagnosis; half of those in whom it has metastasized die within six months—cancer in the pancreas is not necessarily a death sentence.

  The difference is that pancreatic cancers arise from the pancreatic cells themselves; this is the kind that killed actor Patrick Swayze in 2009. But cancers in the pancreas, called neuroendocrine tumors, arise from islands of hormone-producing cells that happen to be in that organ. Jobs learned in 2003 that he had an extremely rare form of this cancer, an islet-cell neuroendocrine tumor. As the name implies, it arises from islet cells, the specialized factories within the pancreas that produce and secrete insulin, which cells need in order to take in glucose from the food we eat. Unlike pancreatic cancer, with neuroendocrine cancer ''if you catch it early, there is a real potential for cure,'' says cancer surgeon Joseph Kim of City of Hope, a comprehensive cancer center in Duarte, California.

  But although neither Apple nor those close to Jobs were willing to discuss the treatments he elected or the course of his disease, interviews with experts on neuroendocrine tumors suggest that some of the choices he made did not extend his life and may have shortened it. [...] Despite the expert consensus on the value of surgery, Jobs did not elect it right away. He reportedly spent nine months on ''alternative therapies,'' including what Fortune called ''a special diet.'' But when a scan showed that the original tumor had grown, he finally had it removed on July 31, 2004, at Stanford University Medical Clinic. In emails to Apple employees immediately after, Jobs said his form of cancer ''can be cured by surgical removal if diagnosed in time (mine was),'' and told his colleagues, ''I will be recuperating during the month of August, and expect to return to work in September.''

(Disponível em: <http://www.thedailybeast.com/articles/2011/10/05/steve-jobs-dies-hisunorthodox-treatment-for-neuroendocrine-cancer.html?obref=obinsite>. Acesso em: 5 out. 2011).

Eating Disorders a New Front in Insurance Fight

By ANDREW POLLACK

Published: October 13, 2011

  People with eating disorders like anorexia have opened up a new battleground in the insurance wars, testing the boundaries of laws mandating equivalent coverage for mental illnesses.

  Through claims and court cases, those with severe cases of anorexia or bulimia are fighting insurers to pay for stays in residential treatment centers, arguing that the centers offer around-the-clock monitoring so that patients do not forgo eating or purge their meals.

  But in the last few years, some insurance companies have re-emphasized that they do not cover residential treatment for eating disorders or other mental or emotional conditions. The insurers consider residential treatments not only costly — sometimes reaching more than $1,000 a day — but unproven and more akin to education than to medicine. Even some doctors who treat eating disorders concede there are few studies proving that residential care is effective, although they believe it has value.

(Disponível em: <http://www.nytimes.com/2011/10/14/business/rulingoffers-hope-to-eating-disorder-sufferers.html?hp>. Acesso em: 5 out. 2011).